Literature DB >> 33641940

OPTICC: A multicentre trial of Occult Pneumothoraces subjected to mechanical ventilation: The final report.

Thomas W Clements1, Marco Sirois2, Neil Parry3, Derek J Roberts4, Vincent Trottier5, Sandro Rizoli6, Chad G Ball7, Zhengwen Jimmy Xiao8, Andrew W Kirkpatrick9.   

Abstract

INTRODUCTION: Patients with occult pneumothorax (OPTX) requiring positive-pressure ventilation (PPV) face uncertain risks of tension pneumothorax or chest drainage complications.
METHODS: Adults with traumatic OPTXs requiring PPV were randomized to drainage/observation, with the primary outcome of composite "respiratory distress" (RD)).
RESULTS: Seventy-five (75) patients were randomized to observation, 67 to drainage. RD occurred in 38% observed and 25% drained (p = 0.14; Power = 0.38), with no mortality differences. One-quarter of observed patients failed, reaching 40% when ventilated >5 days. Twenty-three percent randomized to drainage had complications or ineffectual drains.
CONCLUSION: RD was not significantly different with observation. Thus, OPTXs may be cautiously observed in stable patients undergoing short-term PPV when prompt "rescue drainage" is immediately available. As 40% of patients undergoing prolonged (≥5 days) ventilation (PPPV) require drainage, we suggest consideration of chest drainage performed with expert guidance to reduce risk of chest tube complications. LEVEL OF EVIDENCE: Therapeutic study, level II.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Critical care; Occult pneumothorax; Pneumothorax; Positive-pressure ventilation; Tube thoracostomy

Year:  2021        PMID: 33641940     DOI: 10.1016/j.amjsurg.2021.02.012

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

Review 1.  Complications associated with pre-hospital open thoracostomies: a rapid review.

Authors:  Stian Mohrsen; Niall McMahon; Alasdair Corfield; Sinéad McKee
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2021-12-04       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.